Strategic National Stockpile chief Robert Kadlec focused on biodefense — and a former client, Emergent BioSolutions, benefited

After Robert Kadlec was confirmed as President Trump’s top official for
public health preparedness in 2017, he began pressing to increase
government stocks of a smallpox vaccine. His office ultimately made a
deal to buy up to $2.8 billion of the vaccine from a company that once
paid Kadlec as a consultant, a connection he did not disclose on a
Senate questionnaire when he was nominated.

Publisher: Washington Post | Author: Jon Swaine

TAGS
conflict of interest, corruption, covid-19, national security, and trump cabinet
DATE PUBLISHED
2020-05-05 (Modified: 2020-05-04)

STAR RATING
[Total: 0   Average: 0/5]
VIEW RESOURCE
https://www.washingtonpost.com/investigations/before-pandemic-trumps-stockpile-chief-put-focus-on-biodefense-an-old-client-benefited/2020/05/04/d3c2b010-84dd-11ea-878a-86477a724bdb_story.html

Leave a Reply